IJBPAS, October, 2022, 11(10): 4667-4678

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

QUALITY RISK MANAGEMENT (QRM): A REVIEW

V.ASWINI[1*] AND K.KATHIRESAN[2]

1: PG Student, Department of Pharmacy, Annamalai University, Chidambaram, Annamalai Nagar-608 002, Tamil Nadu

2: Associate Professor, Department of Pharmacy, Annamalai University, Chidambaram, Annamalai Nagar-608 002, Tamil Nadu

***Corresponding Author: V. Aswini: E Mail: v3aswiniv3@gmail.com**

Received 26th Dec. 2021; Revised 24th Jan. 2022; Accepted 14th Feb. 2022; Available online 1st Oct. 2022

https://doi.org/10.31032/IJBPAS/2022/11.10.6484

ABSTRACT

The Pharmaceutical Quality Research Institute Manufacturing Technology Committee (PQRI-MTC) has appointed a risk management task force to coordinate industry case schedule to improve understanding and applicability of ICH Q9. The ICH Q9 guidance will help the industry get started with risk management plan, implementation and practice seems to be challenged. Quality Risk Management (QRM) approach, established by regulatory agencies with accredited management tools, allows for a risk-based advanced towards to quality management in conjunction with statistical tools, which ensures that resources are utilized in accordance with Good Manufacturing Practice (GMP). This article describes to analyze risk for a quality organization and guidance the way to achieve quality management and observation through quality risk management.

Keywords: Quality risk management, Good manufacturing practice, Implementation, Tools, Process, Technology transfer

INTRODUCTION:

ICH Q9 QRM provides a great level substructure as the use of risk administration applications through pharmaceutical improvement and decision making application for production quality. The PQRI-MTC has appointed a small working group and representatives of the Food and Drugs Act to produce good documentation of the real risk management implementation of large pharmaceutical and biopharmaceutical

[1]. In general, risk is the probability of damage. Over time, the modernization of pharmaceutical plants and equipment became necessary. Current production techniques used the pharmaceutical industry are far behind those used in the detergent industry. The United Stated Food and Drug Administration (FDA) said in a 2004 report that pharmaceutical manufacturing activities are inefficient and expensive compared to other industries **[2]**. The change of advent of present day engineering system layout principles, new dimension and manage technologies, control structure is slowing down in the pharmaceutical industry. ICH Q9 provides businesses with at sustainable path to risk management activities, which means that the risk based approach is systematically adopted by GMP regulators **[3]**. Not only do businesses follow it, but even regulators use their own work activities. Various such as the FDA Risk Rating and Filtering Tool of 2004, the EU Analysts Working Party Initiative of 2008 and the PIC/S (Drug Research Conference and Drug Research Co-operation Program) and the 2011 Risk Based Research Planning Tool there are tools and program **[4]**. The test reduces risks for the quality of the system. This helps identify the parts of the system that are working properly (i.e., they will pass the tests). This helps identify ways to optimize the system.

PRINCIPLE:

The ideas of fine danger control are:

- Assessing danger for fine need to be primarily based totally on medical know-how and in the long run connected to affected person safety; And
- The effort, technique and high satisfactory of the High satisfactory hazards control method must be associated with the extent the hazards.

In addition, the pharmaceutical enterprise and regulates can examine and controlled hazards the use of authorized hazard control gear and/or inner procedure (e. g, fashionable working producers) below is whole listing of a few gear.

- Basic risk management facilitation methods;
- **FMEA** (Failure Mode Effect Analysis);
- **FMECA (**Failure Modes, Effect and Criticality Analysis**);**
- **FTA** (Fault Tree Analysis);
- **HACCP** (Hazard Analysis and Critical Control Point);
- **HAZOP** (Hazard Function Analysis);
- **PHA** (Preliminary Hazard Analysis);

- Risk Classification and Filtering;
- Support Statistical Tool.

SCOPE:

This project used to fix known problems or to implement continuous quality improvements. These requirements apply to all new and existing GMP areas and operations, process methods, resources, equipment and procedures **[5]**. These functions include development, production and sales, lifetime inspection and shipping / testing processes for pharmaceuticals (including raw materials, solvent displays, packaging and labeling products). Pharmaceutical manufacturers are included in this report for efficient quality monitoring of product development and production operations, FDA quality control guidelines for each case study (applicable quality, system quality, facilities and technology, product, packaging and labeling, or laboratory control) consistent with the document, contracted risk methodology, classification, understanding and potential use are easily identified by readers **[6]**. This report contains no medical device examples, case studies and the stools shared here are equally suitable for goddess power generation.

QUALITY RISK MANAGEMENT PROCEDURE:

QRM is the systematic operation for authority, reviewing, conducting, evaluating and evaluation (clinical) risks for the quality of the pharmaceutical product life process. An example diagram for QRM is described **(Figure 1)**. The other model can be used. The importance of each element of the structure can vary from topic to topic, but a robust process involves considering all elements on an integral level and an associated level **[7]**.

RISK ASSESMENT:

Risk assessment includes of the identified trouble, the hazards of the analysis and the assessment of the risk related with manifestation to the hazards. Quality assessment well-defined problem are interpretation **[8]**. Risk assessment take hold into account the likelihood of a disaster combined with the severity of that event. The steps comprise risk identification, risk analysis and risk assessment. The risk assessment procedure incorporates of three steps.

- The first step is identification, with a list of potential risks related to the target process or complaint.
- Risk analysis, in which the potential damage of the risks is calculated

quantitatively and qualitatively or both for better analysis and decision-making.

- The third step is the decision step, in which it is decided which risks should be minimized and which are acceptable; decision really needs to be justified.

Risk Recognition is a well order use as information to identify hazards that relate to the riskquestion or problem elucidation **[9]**. The details can include theoretical analysis, opinions and concerns from stakeholders based on theoretical data, which form the basis for additional steps in the quality risk management system.

Risk Analysis is the assessment of risk connected with the identified risk. For some administration tools, the ability to detect damage also plays a role in risk assessment **[10]**. The risk level is based on the assignment, the ability to identify the probability and type of failure or to prevent the cause of the failure, a quantity number (S × L × D) called the risk priority number (RPN), and the resulting risk measure level.

H=High,

M= Medium,

L=Low,

*S=Severity,

L= Likelihood,

D=Detection.

The risk assessment contrast recognized and analyzed risk with the specified risk basis using a qualitative and quantitative scale in order to determine the risk. S × L: Based on the hardness rating multiplied by the likelihood rating, a threshold for the level of risk is established. Approve by holder and QA **[11]**.

SELECTION OF RISK MANAGEMENT TOOLS:

The following instruments are adapted to the risk for a specific area according to the type of risk **[12]**.

- Hazard Analysis Critical Control Point (HACCP).
- Failure Mode Effect Analysis (FMEA).

FAILURE MODE EFFECT ANALYSIS:

FEMA is utilized in form of industries, for hazard control purposes, wherein the identity of hazard known as parameters, and easy quantification of hazard is insufficient. FEMA became delivered with inside the Forties for navy use with the aid of using the US. Industry with inside the US followed Failure Mode Effect Analysis in the Seventies in element due to commercial failures together with the chemical plant ignition in flixboroush UK, in 1974 **[13]**. FMEA method is a scientific technique to

pick out capacity disasters to satisfy a supposed function, to pick out feasible failure reasons so the reasons may be removed, and to discover the effects of disasters so the results may be reduced 182. FMEA used methodically destroy down the evaluation of complicated techniques of plausible steps. Corresponding to ICH Q9, FMEA may be implemented to gadget centers and is probably used to evaluation a production activity and its impact at the product or the procedure **[14]**. For an instance of sensible software of an FMEA, check with Adam *et al*. 183 who executed an FMEA to evaluate the effect of changeability of doubtlessly vital enter variables on combo homogeneity of a pharmaceutical process **[15]**.



Figure 1: General Outlook of Typical Quality Risk Management

RISK CONTROL:

Risk control comprises making decisions about reduction or acceptance. The effort involved in risk manage should be proportional to consequence of the risk **[16]**. Decision making can be used in a variety of processes, including cost-aid analysis, to understand the excellent level of risk control **[17]**.

Risk decrease focuses on the process of reducing or avoiding quality risks when they exceed a certain level. The accomplishment of risk mitigation part can create new risk for the system. The importance of other current risk is Identification and evaluation of potential changes in risk after the accomplishment of the risk reduction procedure **[18]**.

Risk approval is can be a formal determination to approve the enduring risk, or risk can be a determination in which enduring risk are not specified **[19]**. Some kind of damage, quality risk management best practices not to completely eliminate the risk. In this situation, it can be seen that a recognized quality risk management procedure has been used and the quality risk is reduced. Acceptability depends on a number of parameter a case-by-case bottom.

COMMUNICATION OF RISK:

Communication of risk details about risk management between the determination maker and company number. The event can be contacted at any period of the risk management procedure. The publication / the solution of a quality risk management procedure must be applicable connected and documented **[20]**. Can involve stakeholders in communication; E. g, Regulatory and professional, professional and patient, in an organization, industry or regulatory agency, etc. The data collected may be associated with varying degrees of availability, nature, form, likelihood, severity, acceptance, control, treatment, diagnosis or characteristics. It is not required to contact all risk takers. Communication between industry and regulators can be implemented through existing channels regarding quality risk management decisions as set out in regulations and guidelines **[21]**. All processes of the risk management plan and most importantly the publication must be documented and available site practices require the approval of the declaration of deviation. Most importantly, the regulatory authorities involved are properly informed of the recall.

REVIEW OF RISK:

Management of risk should be section of the quality management procedure. A review mechanism shall be implemented to lay hold of within account new knowledge and sustained **[22]**. At all a QRM procedure has been established, the procedure should endure to be applied to happening that influence the quality risk management determination, incase planned or unplanned. The vibration of a rating based on the leveled of risk. The risk review includes the review about the risk receiving determination (Risk control).

IMPLEMENTATION OF QUALITY RISK MANAGEMENT:

This segment deals with the empirical implementation of risk management into the existing quality structure. In the following section, the existing quality subsystem structure within an established quality management system is discussed with consider to the applicability of additional risk management condition **[23]**. This is done by adding new risk requirements to existing processes wherever attainable. If the integration of some requirements is not attainable or desired, these elements remain separate **[24]**. For each quality system considered, possible risks and risks are defined and management instruments are presented to counter these risks.

RISK MANAGEMENT STRATEGY:

The risk management system typically includes a risk management strategy that relates to the overall intent and direction of the company's risk. In general, the risk strategy includes a commitment to the company's regulatory requirements and is intended to enable continuous improvement of the risk management system. The guideline becomes part of the overall quality universal. According to ICH Q10227, a quality general containing the description of the pharmaceutical quality could be created **[25]**.

RISK BASED QUALITY MANAGEMENT:

Change is unpreventable in the pharmaceutical industry as suppliers change their processes, sources and raw material statements, equipment must be repaired, repaired or replaced, locations change, batch sizes increase or decrease, and advances in technology need changes to existing operations **[26]**. A conventional change control procedure is an important essential of modern pharmaceutical quality management to ensure that all changes to products, processes, equipment, facilities, etc. Are established, assessed and properly operation

to protect product quality, eventually ensure safety and effectiveness a system of pharmaceutical products.

DEVIATION MANAGEMENT:

Deviations in drug manufacturing pose a significant risk ahead of quality of a drug and its regulatory observation. Potential risks arise when a procedure is not followed, process framework fluctuate or are not complied with, and an analytical method cannot be performed due to a device failure. A Risk management in composite with deviation management can increase the effectiveness and potency of the deviation management process, since this procedure actually exists **[27]**. There is a tendency to report any nonconformity as a deviation. This can lead to insufficient root cause research and superficial corrective and preventive measures.

Correct operating of all deviations that have occurred can immobilize the assets that would be needed away. In view of this, it is preferable to allocate resources according to the importance of each deviation **[28]**. Additional resources are used to assess the criticality of each individual deviation. Based on the described of the interpretative points in the process and the interpretative quality features about the product, an initial selection of the deviations that have occurred can be made.

RISK-ESTABLISHED RAW MATERIAL SUPPLIER REQUIREMENTS:

Since pharmaceutical companies, the supplier requirement is GMP. Directive 2011/83 / EG250, holder of the product approval, should determine which XP is suitable for use in medical devices by establishing appropriate good manufacturing practice **[29]**. In form toensure the consistent quality, effectiveness and safety of a finished dosage form, the pharmaceutical raw materials must therefore be suitable quality and purity for use in performed pharmaceutical products. Pharmaceuticals rely heavily on raw material suppliers to contribute materials with attire chemical and physical properties and consequently consistently high quality appropriated **[30]**. It is evident that numerous quality defects in the surfaces of this product can result from poor property of the raw material.

PHARMACEUTICAL COMPLAINT MANAGEMENT:

Complaint from the pharmaceutical industry relate to product quality defects that were presented to the customer or the end user for the first time **[31]**. Complaint can be due to defects in the packaging material, **(Table 1)** e.g. B. a leaky bottle, a difficult-to-

open cap or a tablet is missing from the blister, or refer to the pharmaceutical dosage form. E. g, the medicine has no consequence, the color of the solution is different, or a broken tablet has been found. The goal of complaint management is to record a compliant management is to record incoming complaint, carry out proper investigations, implement CAPA provided necessary, and respond to the customer.

Table 1: General outlook of compliance risk estimation

COMPLIANCE RISK ESTIMATION	
COMPLAICE ISSUE	**COMPLAINCE RISK**
> 5 important findings during the last self-assessment.	**High**
>8 deviation and/or grievance with root reasons traced returned to the department.	
Important changes have been made to products, processes, services, equipment and facilities.	
1-5 important findings from the last self-assessment.	**Medium**
4-8 Deviations and / or complaints with causes that can be traced back to the department	
Minor changes have been made to products, processes, services, equipment and facilities.	
No significant findings at the last self-assessment.	**Low**
> 4 basic causes of deterioration and / or complaint that are returned to the department.	
No change control resent changes.	

RISK POSITIONED PLANNING OF SELF INSPECTION:

The self-inspection regularly checks instruction or part of a quality assurance system by an internal committee to check whether the GMPs are being applied and to recommend corrective measures that are required by the responsible management. And following good manufacturing practice guidelines and taking necessary corrective action **[32]**. There are various options for planning and performing the self-assessment. For example, self-inspections could be carried out by sector and all GMP-relevant areas are checked annually. Resources this goal is rarely achieved. Another possibility of self-censorship is a product-centric approach, in which all applicable systems and processes associated with a particular product can be examined. A specific process can also be selected, e.g. focus on the accurate process flow and the required inputs and outputs.

CONCLUTION:

Risk between risk and reward is never more important than it is now in the pharmaceutical industry because many established processes and protocols surrounding risk management are focused on detecting compliance failures or violations of law and regulations. Quality risk management is the fundamental procedure

for evaluating, regulating, communicating and reviewing the risks to quality of a drug throughout the entire product life process. QRM helps with risk management for the patient and the organization. Various manufacturing issues arise later or during the bulk release. This leads to complex and costly inquiries and other serious quality issues that ultimately lead to product recalls and crashes. QRM promotes decision-making in the event of quality problems and provides a systematic process for coordinating, facilitating and improving risk-based decision-making in relation to risks.

REFERENCES:

[1] CFR 120 (2001): Hazard Analysis and Critical Control Point (HACCP) System. Code of Federal Regulations, United States.

[2] Accenture (ed.) (2011): Report on the Accenture 2011 Global Risk Management Study. Risk management as a source of competitive advantage and high performance.

[3] Adam, S.; Suzzi, D.; Radeke, C.; Khinast, J.G. (2011): An integrated Quality by Design (QbD) approach towards design space definition of a blending unit operation by

[4] Discrete Element Method (DEM) simulation. In: European Journal of Pharmaceutical Sciences, Vol. 42, pp. 106-115.

[5] Agerberg, J.-N.; Agren, J. (2012): Risk management in the tendering process. A survey of risk management practices within the infrastructural construction. Göteborg, Sweden:

[6] Department of Technology Management and Economics, Chalmers University of Technology, Master Thesis.

[7] Aghili, S. (2010): Organizational risk management: successful achievement of business objectives inges on the organization's ability to manage risk effectively. In: Internal Auditor, Vol. 67, No. 3.

[8] Appelbaum, S.H.; Habashy, S.; Malo, J.-L.; Shafiq, H. (2012): Back to the future: revisiting Kotter's 1996 change model. In: Journal of Management Development, Vol. 31, No. 8, pp. 764-782.

[9] Arling, E.R.; Dowling, M.E.; Frankel, P.A. (2008): Role of quality systems and audits in pharmaceutical manufacturing environment. In: Gad, S.C. (ed.): Pharmaceutical manufacturing handbook – Regulations and Quality. New Jersey: John Wiley & Sons, Inc.

[10] Armenakis, A.A.; Harris, S.G. (2009): Refelctions: our journey in organizational change research and practice. In: Journal of Change Management, Vol. 9, No. 2, pp. 127-142

[11] FDA News – GMPs for the 21st Century; M Anisfeld; Industrial Pharmacy, Dec 2004, I4, P20. ICH Harmonized Tripartite Guideline. ICH Q8 (R2): Pharmaceutical Development. August 2008; http://www.ich.org.

[12] ICH Harmonized Tripartite Guideline. ICH Q9: Quality Risk Management June 2006; http://www.ich.org.

[13] EU GMP Requirements – Quality Systems; Boedecker B, Germany; Presentation 20-21 Oct 2009, Ankara, Turkey Ministry of Health.

[14] WHO guidelines on quality system requirements for national GMP inspectorates: http://www.who.int/medicines/areas/quality_safety/quality_assurance/inspections/en/index.html.

[15] ICH-webpage publishing; ICH harmonized points to consider for ICH Q8/Q9/Q10 implementation, 6 December 2011 (FIP, AM and IFPMA) (http://www.ich.org).

[16] Frank T *et al*. Quality risk management principles and industry case studies (December 2008) sponsored by the Product Quality Research Institute Manufacturing Technology Committee (PQRI-MTC) (http://www.pqri.org).

[17] Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2011 (CD-ROM) (http://www.who.int/medicines/areas/quality_safety/ quality assurance/guidelines/en/index.html).

[18] Pharmaceutical cGMPs for the 21st century – A risk-based approach. US Food and Drug Administration, Center for Drug Evaluation and Research (FDA CDER), September 2004 (http:// www.fda.gov/Drugs/default.htm).

[19] MHRA guidance: GMP-QRM – Frequently asked questions (http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/ Good Manufacturing Practice/FAQ/Quality Risk Management/index.htm).

[20] Guidance for industry "Q9 Quality Risk Management" by US department of Health and Human Services, Food and drug Administration, Center for Drug and Evaluation Research, June 2006.

[21] WHO Guideline on Quality Risk Management A draft guidance August 2010.

[22] Implementation of ICH Q9 in the pharmaceutical field an example of methodology from PIC/S 2010.

[23] Prashant Kumar Katiyar, Risk analysis and risk management in pharmaceutical

industry International journal of pharma world research (an international quarterly pharmaceutical research journal), vol 1 2010.

[24] Risk assessment and quality control by Max Williams, MPA, November 2012.

[25] Quality Risk Management- the pharmaceutical experience annomahony 11 november 2011.

[26] Kelvinc Pharmaceutical engeneering vol 28 no 3 GAMP 5-A Quality Risk Management Approach may/june 2008.

[27] Health and Safety Briefing, Fault Tree Analysis, Pg. No. 26, Dec. 2006.

[28] IEEE Xplore, Data Management Tool for Aiding the Hazard and Operability Analysis Process, Page(s):1-4, Aug. 2006.

[29] Failure Mode and Effect Analysis: FMEA from Theory to Execution, D. H. Stamatis 2nd Edition 2003.

[30] WHO Technical Report Series No. 908, 2003, Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals.

[31] Risk Management: Guidelines and Best Practices Missoun Information Technology Advisory Board Project Management Committee Risk Management Subcommittee November 2003.

[32] Risk Management Vocabulary Guidelines for Use in Standards, International organization for standardization, Jan 1, 2002.